Runda Medical(SH:603108)2024-04-26 14:17Financial Performance - Total operating revenue for Q1 2024 was ¥2,072,478,429.77, a decrease of 4.85% compared to ¥2,178,109,255.75 in Q1 2023[2] - Net profit for Q1 2024 was -¥5,573,183.84, compared to a net profit of ¥64,806,486.79 in Q1 2023, indicating a significant decline[10] - Basic earnings per share for Q1 2024 were ¥0.04, down from ¥0.14 in Q1 2023[3] - The company reported a total comprehensive income of ¥48,547,632.78 for Q1 2024, down from ¥119,970,835.41 in Q1 2023[3] - Other income for Q1 2024 was ¥5,825,014.08, compared to ¥9,052,231.33 in Q1 2023, a decrease of 35.5%[2] - Net profit for Q1 2024 was CNY 47.52 million, a decrease of 60.24% compared to CNY 119.35 million in Q1 2023[30] - Operating profit decreased to CNY 83.60 million, down 45.29% from CNY 152.16 million in the same period last year[30] - Net profit attributable to shareholders was ¥22,603,808.03, down 72.11% year-over-year[52] Cash Flow - Cash received from sales and services in Q1 2024 was ¥2,186,679,204.64, a decrease from ¥2,300,584,530.87 in Q1 2023[5] - The net cash inflow from operating activities for the first quarter of 2024 is -40,845,966.27 RMB, compared to -129,971,560.02 RMB in the previous period[17] - Cash received from operating activities totaled 2,219,850,447.83 RMB, while cash paid for goods and services was 1,722,711,473.93 RMB[17] - The net cash flow from financing activities for Q1 2024 was ¥112,441,214.50, a decrease of 37.0% compared to ¥178,384,765.99 in Q1 2023[18] - Cash inflow from operating activities totaled ¥614,228,590.00, down from ¥967,772,744.97 in the previous year[54] - Cash outflow from operating activities was ¥807,214,856.99, resulting in a net cash flow from operating activities of -¥192,986,266.99[54] Expenses and Costs - Total operating costs for Q1 2024 were ¥1,947,948,529.99, down 4.48% from ¥2,039,063,187.87 in Q1 2023[2] - Research and development expenses for Q1 2024 were ¥29,059,209.46, down from ¥32,638,835.84 in Q1 2023, reflecting a 10.5% reduction[2] - Financial expenses for Q1 2024 were ¥80,652,587.02, a slight decrease from ¥83,438,804.10 in Q1 2023[2] - The company experienced a significant increase in tax and additional fees, totaling ¥11,491,620.14 in Q1 2024, compared to ¥11,567,573.51 in Q1 2023[2] Assets and Liabilities - The total current assets as of March 31, 2024, amounted to ¥3,172,368,700.45, an increase of 1.3% from ¥3,132,813,040.91 at the end of 2023[22] - The total liabilities as of March 31, 2024, were ¥5,272,833,334.13, slightly up from ¥5,241,745,365.60 at the end of 2023[23] - The company's total assets reached ¥8,114,364,972.94 as of March 31, 2024, compared to ¥8,068,649,586.26 at the end of 2023[23] - The company's long-term borrowings decreased to ¥172,500,000.00 in Q1 2024 from ¥263,415,000.00 in Q4 2023, a reduction of 34.5%[23] - The accounts receivable increased to ¥5,699,356,730.13 as of March 31, 2024, from ¥5,539,609,452.80 at the end of 2023, indicating a growth of 2.9%[26] Shareholder Information - The total number of common shareholders at the end of the reporting period is 51,798[13] - The largest shareholder, Hangzhou Gongshu District State-owned Investment Group Co., Ltd., holds 116,000,000 shares, representing 19.37% of total shares[13] - Liu Hui and Zhu Wenyi each hold 31,528,771 and 31,518,408 shares, respectively, both representing 5.26% of total shares[13] Strategic Initiatives - The company plans to enhance its market expansion strategies and invest in new product development to recover from the current financial downturn[31] - The company is currently evaluating potential mergers and acquisitions to strengthen its market position and diversify its product offerings[31] - The company has no new strategies or significant changes in shareholder structure reported for the period[16] Other Financial Metrics - The basic and diluted earnings per share for Q1 2024 were both -¥0.01, compared to ¥0.11 in Q1 2023[24] - The cash and cash equivalents decreased by ¥1,402,981.65 in Q1 2024, contrasting with an increase of ¥23,915,909.10 in Q1 2023[18] - The company's cash and cash equivalents at the end of Q1 2024 were ¥611,884,719.64, down from ¥466,206,613.92 in Q1 2023[18] - The weighted average return on equity decreased by 1.53 percentage points to 0.53%[53]